The role of genotype-environment interaction in the pregnancy-related diseases

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000029178

Enrollment

Unknown

Registered

2020-01-17

Start date

2020-01-14

Completion date

Unknown

Last updated

2020-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy-related diseases

Interventions

Pregnancy related disorders group:Nil

Control group:Nil

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Clinical diagnosis of gestational diabetes, pregnancy-induced hypertension or gestational intrahepatic cholestasis in women; Gestational diabetes mellitus (GDM): according to the international association of diabetes and pregnancy research groups (IADPSG), the diagnosis of GDM is based on the oral glucose tolerance test (OGTT) of 75g1 h glucose 180 mg/dL (10.0 mmol/L) or 2 h glucose 153 mg/dL (8.5 mmol/L). Pregnancy-induced hypertension(PIH): a diagnosis of pregnancy-induced hypertension that meets at least one of the following criteria, blood pressure 140/90 mmHg appears for the first time during pregnancy and returns to normal after 12 weeks postpartum or blood pressure 140/90 mmHg after 20 weeks with newly diagnosed proteinuria. Intrahepatic cholestasis during pregnancy (ICP): diagnosis is based on clinical symptoms and laboratory tests, including severe pruritus during pregnancy, and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and elevated serum total bile acid (TBA) levels in the absence of skin rash in the second trimester of pregnancy (>10 mmol/L); 2. Monocyesis; 3. Understand the purpose of the clinical study and voluntarily sign the written informed consent.

Exclusion criteria

Exclusion criteria: 1. Refusal or unwillingness to sign a written informed consent; 2. Unable to cooperate with sample collection and related inspection; 3. Having type 1 and type 2 diabetes, autoimmune and inflammatory diseases, oncology, cardiovascular disease, kidney disease, liver disease, and chronic infections may affect the outcome of the study; 4. Participated in other scientific research projects.

Design outcomes

Primary

Measure	Time frame
SNP;environmental factors;mRNA;DNA methylation;Non-coding RNA;Copy number variation;genotype-environment interaction;	—

Countries

China

Contacts

Public ContactHongsong Yu

Zunyi Medical University

yuhongsong@163.com+86 13368394403

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 24, 2026